26Jul2018 Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios? /Luke Timmerman/1/All, Venture Capital26 Jul 2018 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.